Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept for Anemia in del(5q) Myelodysplastic Syndromes Refractory to ESAs and Lenalidomide
2024-519310-31-00Phase 2Authorised
- Sponsor
- Qol-one
- Start
- Jan 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in 5q deletion syndrome and Myelodysplastic Syndrome (MDS), sponsored by Qol-one. Primary endpoint: Red blood cell transfusion independence (8 weeks in first 24 weeks). Planned start Jan 2025; status: authorised.
02
Drugs
luspatercept
03
Conditions
5q deletion syndromeMyelodysplastic Syndrome (MDS)
Beyond the preview
Go deeper on 2024-519310-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519310-31-00.